Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology shared on LinkedIn:
“Most patients with bladder cancer meet a urologist first. Many also need a medical oncologist, and sometimes a radiation oncologist, before the plan is set.
On November 14 at the OneOncology Annual Conference in Nashville, I’m on the bladder panel with Dr. Suzanne Merrill of Colorado Urology, who takes NMIBC. I take MIBC. Dr. Geoffrey Sklar, CMO of United Urology Group, moderates.
BCG-unresponsive NMIBC has more bladder-sparing options than it used to. In MIBC, NIAGARA, KEYNOTE-905 and VOLGA each added immunotherapy or enfortumab vedotin around cystectomy. Reinforces need for multiD in community practice, where the two clinics may sit in different buildings or different groups. It’s also where many of our patients get their care.
What has worked in your practice to get urology and medical oncology talking before the first treatment decision.”
You can also read:
- Katy Beckermann: OneOncology Annual Conference Expands Its Focus on Multidisciplinary GU Cancer Care
- VOLGA at ESMO 2026: Perioperative Durvalumab With or Without Tremelimumab Plus Enfortumab Vedotin in MIBC
- KEYNOTE-905 at ESMO 2026: Perioperative Pembrolizumab With or Without Enfortumab Vedotin in MIBC
